Trials / Withdrawn
WithdrawnNCT02338531
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jules Bordet Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic triple-negative breast cancer patients with residual disease (cHEmoresistant) after completion of standard neoadjuvant chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-03084014 | |
| PROCEDURE | Breast cancer surgery |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2018-09-01
- Completion
- 2018-12-01
- First posted
- 2015-01-14
- Last updated
- 2016-04-29
Locations
5 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT02338531. Inclusion in this directory is not an endorsement.